in this issue
Regions :: North America :: Canada
Lonza Offers to Acquire Patheon
6:31 AM MDT | August 21, 2009 | Deepti Ramesh
Lonza says it has submitted a non-binding proposal to acquire all of the outstanding restricted voting shares of leading pharmaceutical contract manufacturing and development services company Patheon (Toronto) at a price of $3.55/share. The price offered by Lonza is significantly higher than the offer made by private equity firm JLL of $2/share, say press reports. “An acquisition of Patheon would take us into the complementary activities of finished dosage development and manufacturing for both small molecule and biological active ingredients,” says...
This information is only available to Chemical Week subscribers.
Forgot your user ID or password?
Not an IHS Chemical Week member yet?
Here's why you should be:
100% Satisfaction Guarantee